Vetanic

Based in Tokyo, Japan, Vetanic Inc. d. b. a Vetanic is dedicated to advancing animal regenerative medicine through innovative solutions using induced pluripotent stem (iPS) cell technology for veterinary applications.

Founded in 2021, Vetanic Inc. focuses on animal regenerative medicine. The firm has received three rounds of funding, with the latest being a undisclosed round in April 2026 raising an undisclosed amount from Kohjin Bio Co. , Ltd.

and Sysmex. The company is led by Akinori Mochizuki, who serves as both the CEO and Founder. Vetanic specializes in animal regenerative medicine, focusing on the development and application of iPS cell technology. Their offerings include generating canine iPS cells and differentiating them into canine mesenchymal stem cells (MSCs) for regenerative medical products.

These products address health issues in companion animals, particularly dogs, and are validated through research with leading institutions. Vetanic operates by commercializing regenerative medical products derived from their proprietary iPS cell technology. Revenue is generated through partnerships with veterinary clinics and research institutions, utilizing licensing agreements for their technology and selling developed regenerative products, including custom therapies for individual animals. The company plans to use April 2026 funds to strengthen its value chain from R&D to commercialization and accelerate the development of iPS‑cell‑derived animal regenerative medicine for global markets.

The company aims to introduce new regenerative medical products while expanding into wider markets beyond Japan as regulatory approvals are secured.